Breast Cancer Therapeutics Market Is Expected to Post a CAGR of 58.3% From 2015 to 2023: Transparency Market Research

ALBANY, N.Y.–(BUSINESS WIRE)–Growth in the global breast cancer therapeutics market will be
unprecedented, says a latest report by Transparency Market Research. The
market is expected to post a CAGR of 58.3% between 2015 and 2023, as it
grows from its 2015 valuation of 55.5 million to US$7,853.1 million by
2023. These findings are detailed in the report titled ‘Breast Cancer
Therapeutics: Pipeline Analysis Market – Global Industry Analysis, Size,
Share, Growth, Trends and Forecast 2015–2023
.’

Browse Report: http://www.transparencymarketresearch.com/breast-cancer-therapeutics-pipeline-analysis-market.html

The vigorous growth of the breast cancer therapeutics market comes as
little wonder in the backdrop of the fact that the WHO has found breast
cancer to be the second most prevalent type of cancer globally. The
America Cancer Society expects about 231,840 women to be diagnosed with
the disease in 2015 – and these figures are for the U.S. alone. Thus,
the sheer rise in the prevalence of breast cancer makes it a space where
novel molecules and therapies are imperative.

Get Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5678

The report segments the global breast cancer therapeutics market on the
basis of clinical study phases into: Phase I, phase II, and phase III
drugs. Of these, the report closely evaluates breast cancer drugs that
are currently in phase III of clinical trials. Phase III drugs that are
studied in great detail in the breast cancer therapeutics market report
are: Palbociclib (PD-0332991) + Exemestane, BKM120, Neratinib, DOXIL,
NKTR-102, ABP 980, NK105, CT-P6, and Olaparib.

Browse Press Release: http://www.transparencymarketresearch.com/pressrelease/breast-cancer-therapeutics-pipeline-analysis-market.htm

Neratinib (Puma Biotechnology, Inc.), a clinical trial phase III drug,
will rake in maximum revenue by 2023. The drug is important to the
breast cancer therapeutics market because it is highly potent as an
irreversible tyrosine kinase inhibitor (TKI). At the second place, in
terms of revenue generation, will be Pfizer, Inc’s Palbociclib,
Fulvestrant.

Browse Article: http://www.transparencymarketresearch.com/article/breast-cancer-therapeutics-pipeline-analysis-market.htm

About TMR

Transparency Market Research (TMR) is a market intelligence company
driven by high-pedigree consultants and researchers. TMR leverages its
Syndicated Research, Custom Research, and Market Consulting expertise to
help businesses make accurate decisions. TMR’s exclusive blend of
quantitative forecasting and trends analysis draws on proprietary data
sources and techniques, while their data repository is continuously
updated to reflect the latest trends.

Contacts

Transparency Market Research
Mr. Nachiket Ghumare, +1-518-618-1030
USA-Canada
Toll Free: 866-552-3453
sales@transparencymarketresearch.com
http://www.transparencymarketresearch.com/